DuPont Merck licenses ImaRx (US) agent:
This article was originally published in Clinica
ImaRx (US) has licensed its cardiovascular ultrasound contrast agent, MRX-115, to DuPont Merck. When ImaRx completes Phase II trials, due to start this month, DuPont Merck will assume responsibility for clinical development of the agent. In return for exclusive rights to MRX-115 for cardiology and radiology diagnostic applications in the Americas and cardiology applications in the EU, DuPont Merck will make up-front, milestone and royalty payments. ImaRx will retain rights to radiology applications in the EU and all rights in other regions.